Navigation Links
Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Date:10/30/2007

risks identified in Synvista Therapeutics' filings with the Securities and Exchange Commission. Further information on risks faced by Synvista are detailed under the caption "Risk Factors" in Synvista Therapeutics' Annual Report on Form 10-K for the year ended December 31, 2006. These filings are available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Synvista Therapeutics undertakes no obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Synvista Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. VBI Provides Potential Targets to Diabetes Therapeutics
2. CELL THERAPEUTICS PAYS Heavily to Resolve Dispute FOR ALLEGED ILLEGAL MARKETING OF CANCER DRUG
3. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
4. Researchers Present Ways To Reduce The Risk Of Dementia
5. Researchers Present Data Regarding The Efficiency Of Herbs
6. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
7. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
8. Drug Reactions First Present Themselves In The Mouth
9. Reminiscing Into The Past Makes You Dissatisfied With The Present
10. Living In The Past Indicates Dissatisfaction With Present
11. Movies Represent Coma In A Wrong Way
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2008)...July 9 /PRNewswire/ -- leViv, Inc. (http://www.le... nutrition and lifestyle programs for,individual h.... The new,programs include 28-days of delicious, d...r 110 items in every order), online recipes, healt...urces, professional advice,news, health informati...
(Date:7/9/2008)... /PRNewswire-FirstCall/ - MDS Inc. (TSX: MDS; NYSE...s to the global life,sciences markets, today annou...mited (AECL) with notice of arbitration proceeding...fulfill its contractual obligations,under its 2006...d if not,granted, seeking significant monetary dam...
(Date:7/9/2008)... adds to its unparalleled content on breastfeeding... professional articles on child, health, from alle...lking., BOULDER, Colo., July 9 /PRNewswire/ -- Br...verything for the New Mom, improves its already,un... doctor-reviewed,professional articles on infant, ...
(Date:7/9/2008)... DRE, Inc., a premier international surgical...mers that as much as $250,000 in medical equipment...lings. , Louisville, KY (...f 2008, in accordance with Tax Code Section 179, c...t bought in 2008. This could make 2008 an attracti...
Breaking Medicine News(10 mins):Health News:leViv Launches First Meal Programs Specifically Designed for Taste and Health 2Health News:leViv Launches First Meal Programs Specifically Designed for Taste and Health 3Health News:MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files $1.6 Billion Court Claim against AECL and the Government of Canada 2Health News:MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files $1.6 Billion Court Claim against AECL and the Government of Canada 3Health News:Breastfeeding.com Becomes a Premier Resource on Child Health 2Health News:Economic Stimulus Act Can Improve Medical Equipment Purchasing Power 2
...ced which has been found to have less side effects...mmunotherapy vaccines. //Antibodies against the al...nt encounters the allergen or infection these anti...o counteract the allergen which is an antigen. Co...
...n at University of California, San Francisco have ...innovative devices to first remove and then recons...ccess tumors. // Tumors which are present in the b...cult to operate. The neurosurgeon used a new tec...
...igration/Macrophage Inhibitory factor (MIF) which ...ultiple Sclerosis. This new pathway can be used in...in a way progression of Multiple Sclerosis is hind.... Multiple Sclerosis is an autoimmune disease wh...
...t tiagabine, a selective ?-aminobutyric acid (GABA... and next-morning alertness and performance in adu...mnia is characterized by difficulty initiating or ...sleep, which causes clinically significant distres...
Other Medicine News:Health News:Oral Edible vaccine for Allergy Vaccines 2Health News:Macrophage Inhibitory Factor Causes Multiple Sclerosis Progression 2
(Date:7/7/2008)...s scientific evidence supporting accuracy of, it...ajor international co...ly 7 /- Molecular,Biometrics, LLC, a ...el,clinical tools for applications in personalized... function in health and disease, presented data fr...
(Date:7/7/2008)...- Biopure Corporation,(Nasd...sions with the Food,and Drug Administration (FDA) ...r a new clinical trial of Hemopure(R) [hemoglobin ... proposed to study use of Hemopure,in patients suf...efuse,transfusion with blood components. Currently...
(Date:7/6/2008)...f Assay Submitted for FDA Clearance, SAN DIEGO, J...segment,of BD (Becton, Dickinson and Company) (NYS...D GeneOhm(TM) Cdiff molecular assay for the rapid ...nfection (CDI). It is the first CDI,diagnostic tes... one test,procedure. BD has also submitted this as...
(Date:7/3/2008)...Newswire-USNewswire/ -- All newborn infants,should...resent at birth,according to a new recommendation... recommendation and the accompanying summary of ev... Children whose hearing is impaired at birth, duri... with verbal and nonverbal communication and,socia...
Breaking Medicine Technology:Embryo Viability Studies Support Utility of Novel, Metabolomic Profiling Technology 2Embryo Viability Studies Support Utility of Novel, Metabolomic Profiling Technology 3Embryo Viability Studies Support Utility of Novel, Metabolomic Profiling Technology 4Biopure Announces Meeting With FDA 2Biopure Announces Meeting With FDA 3BD Announces CE Marking of a New Molecular Test to Diagnose Patients with Clostridium difficile Infections 2BD Announces CE Marking of a New Molecular Test to Diagnose Patients with Clostridium difficile Infections 3Task Force Recommends Screening for Hearing Loss in All Newborns 2Task Force Recommends Screening for Hearing Loss in All Newborns 3Phase II Study of Zevalin 28R 29 Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 1233 1Phase II Study of Zevalin 28R 29 Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 1233 2Phase II Study of Zevalin 28R 29 Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 1233 3Phase II Study of Zevalin 28R 29 Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 1233 4Phase II Study of Zevalin 28R 29 Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 1233 5Ovarian cancer risk not affected by alcohol and smoking but reduced by caffeine 9872 1Ovarian cancer risk not affected by alcohol and smoking but reduced by caffeine 9872 2Super Thin Drug Free Coating Hides Stent as It Unblocks Heart Arteries 9870 1Super Thin Drug Free Coating Hides Stent as It Unblocks Heart Arteries 9870 2Super Thin Drug Free Coating Hides Stent as It Unblocks Heart Arteries 9870 3Super Thin Drug Free Coating Hides Stent as It Unblocks Heart Arteries 9870 4Deli Chef Tri Bean Salad Recalled From Some Kroger Stores 9868 1
...Point Therapeutics, Inc.,(NASDAQ: POTP) today repo... at the 2007 Annual Meeting of the American,Associ...os Angeles,California, April 14-18, 2007. The AAC...es on talabostat,s novel mechanism of action., Add...follows: , Presentation Date and Time: Monday, Apr...
... - Ascenta Therapeutics,Inc. announced today that...ing compounds will be featured in three oral,prese...week,s 2007,Annual Meeting of the American Associa... Angeles, California April 14-18, 2007., Ascenta,s...t the,"High Impact Late-Breaking Research 1" sessi...
Other Medicine Technology:Ascenta Therapeutics Highlights Multiple Data Presentations at,Upcoming AACR Annual Meeting 2Ascenta Therapeutics Highlights Multiple Data Presentations at,Upcoming AACR Annual Meeting 3Ascenta Therapeutics Highlights Multiple Data Presentations at,Upcoming AACR Annual Meeting 4Ascenta Therapeutics Highlights Multiple Data Presentations at,Upcoming AACR Annual Meeting 5Ascenta Therapeutics Highlights Multiple Data Presentations at,Upcoming AACR Annual Meeting 6
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
Medicine Products: